SCOPE 2018

A CRO monopoly? Sponsors frustrated with lack of options

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/martince2)
(Image: Getty/martince2)
With fewer global mid-sized contract research organizations (CRO) through consolidation, some stakeholders are expressing concern that the industry could become a monopoly – “we may be getting there,” one expert said.

Ratan Ratnesh, director and head, clinical outsourcing, Otsuka, recently spoke at the SCOPE Summit, which took place in in Orland, FL. The presentation focused on the options, consideration, and implications of outsourcing in a market that has, according to Ratnesh, “a limited number of global suppliers​.”

This is a problem from a commodity point of view, he explained. And while he concedes that many of the smaller CROs have alliances, he said this doesn’t work. “It just creates hassle​,” he said.

Global suppliers to some extent … it is becoming a monopoly​,” Ratnesh continued. “It’s not a monopoly yet, but we may be getting there​.”

David Windley, CFA, CPA, managing director, healthcare equity research, Jefferies LLC, said Ratnesh’s comment reflects sponsors continued experience of uneven vendor performance and the desire to have more options.

The frustration has not died​,” he added. “Some of that is born out of unrealistic expectations – and some is driven by legitimate shortfalls in performance by the vendors​.”

However, Windley said the industry is far from becoming a monopoly, as it is still quite fragmented. Though directionally, it has been consolidating.

As part of this, Windley said sponsors no longer have “Goldilock’s choice,” of a medium-sized company that’s not too big and not too small. "The choices in that particular size band are gone​," he said.

You have to choose between a pretty large CRO, or sub $500m​,” Windley added. Though some of the smaller players are doing quite well, but won’t likely reach parity organically.

Organically, it would take way too long for the small companies to grow into that mid-sized CRO space, he said. But inorganically, with the help of private equity, the next medium-sized CRO could be built.

A growing list of private equity players have had really good success in this space​,” said Windley. “That success begets – if not more success – it at least begets interest​.”

What are your thoughts? Is the industry headed towards a monopoly? Email me at

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers